Tech Company Financing Transactions

IconOVir Bio Funding Round

Nextech Invest, Vida Ventures and Bellco Capital invested in a $77 million Series A capital raise for IconOVir Bio. The round closed on 1/6/2021.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

3210 Merryfield Row
San Diego, CA 92121
USA

Phone

Undisclosed

Website

www.iconovir.com

Email Address

[email protected]

Overview

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. The Company's proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O'Shea, Ph.D., of the Salk Institute.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

David Chang

        

Chief Executive Officer

Mark McCamish

        

Controller

Sean Algeo

        

VP - Operations

Benjamin Stone

        

VP - Product Management

Juli DeGraw

        

Browse more venture capital transactions:

Prev: 1/6/2021: NextStep Interactive venture capital transaction
Next: 1/6/2021: iboss Cybersecurity venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary